News
Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
Luxembourg-based steelmaker ArcelorMittal is bringing on lobbying firepower as the steel conglomerate seeks to defend its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback